FDA approves drug for myelofibrosis

Drug Topics, 03/19/2012

FDA approved ruxolitinib (Jakafi), a twice–daily tablet, indicated for the treatment of myelofibrosis, a rare bone marrow disease that affects less than 200,000 people in the United States. Ruxolitinib is a kinase inhibitor, specifically targeting Janus Associated Kinases (JAKs) 1 and 2 that mediate the signaling of cytokines and growth factors relevant to hematopoiesis and immune function. JAKs 1 and 2 initiate recruitment of signal transducers and activators of transcription to the cytokine receptors, which ultimately modulates gene expression.

Print Article Summary Cat 2 CME Report